Sobering portrait of meth use in Crow Wing County leads officials to outline policies | MPR News
Source: Sobering portrait of meth use in Crow Wing County leads officials to outline policies | MPR News
read moreIn Grim Echo of America’s Opioid Crisis, Meth Tears Through Asia – Bloomberg
Source: In Grim Echo of America's Opioid Crisis, Meth Tears Through Asia - Bloomberg
read moreMethamphetamine Is Flooding Into U.S., Drug Officials Say – WSJ
Officials are citing a worrisome increase in methamphetamine trafficking and related deaths around the U.S., tempering otherwise hopeful signs that overall drug-overdose fatalities are finally leveling off. Source: Methamphetamine Is Flooding Into U.S., Drug Officials...
read moreBinding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
Sobering portrait of meth use in Crow Wing County leads officials to outline policies | MPR News
Source: Sobering portrait of meth use in Crow Wing County leads officials to outline policies | MPR News
read moreIn Grim Echo of America’s Opioid Crisis, Meth Tears Through Asia – Bloomberg
Source: In Grim Echo of America's Opioid Crisis, Meth Tears Through Asia - Bloomberg
read moreMethamphetamine Is Flooding Into U.S., Drug Officials Say – WSJ
Officials are citing a worrisome increase in methamphetamine trafficking and related deaths around the U.S., tempering otherwise hopeful signs that overall drug-overdose fatalities are finally leveling off. Source: Methamphetamine Is Flooding Into U.S., Drug Officials...
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.